Sintilimab treatment for chronic active Epstein–Barr virus infection and Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in children

Sintilimab treatment for chronic active Epstein–Barr virus infection and Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in children

Abstract Background Chronic active Epstein–Barr virus infection (CAEBV) and Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) are rare but life-threatening progressive diseases triggered by EBV infection. Glucocorticoid/immunosuppressants treatment is temporarily effective;...

Full description

Bibliographic Details
Main Authors: Ruyue Chen, Qiang Lin, Yun Zhu, Yunyan Shen, Qinying Xu, Hanyun Tang, Ningxun Cui, Lu Jiang, Xiaomei Dai, Weiqing Chen, Xiaozhong Li
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Epstein–Barr virus (EBV)
Chronic active Epstein–Barr virus infection (CAEBV)
Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH)
Programmed cell death 1 (PD-1)
Sintilimab
Online Access:https://doi.org/10.1186/s13023-023-02861-9

Internet

https://doi.org/10.1186/s13023-023-02861-9

Similar Items